VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration

Publisher： Karger

E-ISSN： 1423-0259|51|1|1-8

ISSN： 0030-3747

Source： Ophthalmic Research, Vol.51, Iss.1, 2013-10, pp. : 1-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetic Association with Response to Intravitreal Ranibizumab for Neovascular Age-Related Macular Degeneration in the Han Chinese Population

By  

Ophthalmologica, Vol. 230, Iss. 4, 2013-09 ,pp. : 227-232

Karger

Access to resources Recommend Favorite

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 231, Iss. 2, 2013-12 ,pp. : 80-85

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial

By  

Ophthalmologica, Vol. 234, Iss. 1, 2015-06 ,pp. : 40-54

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab for Patients with Neovascular Age-Related Macular Degeneration with Good Baseline Visual Acuity

By  

Ophthalmologica, Vol. 233, Iss. 1, 2014-11 ,pp. : 27-34

Karger

Access to resources Recommend Favorite